Enhancing the Interferon Pathway to Attack Cancer – Not a One-Size-Fits-All Approach
Dr Christine Ward, Takeda Pharmaceuticals, discusses how Takeda is activating the interferon pathway against hematologic and solid tumors and identifying the patients who may respond better to these therapeutics.
Summary:
In this podcast, you will hear a presentation from Dr Christine Ward, Takeda Pharmaceuticals, from the 2022 Immuno-Oncology 360° Conference regarding novel therapeutic approaches being investigated to harness the innate immune system to enhance the interferon pathway to treat cancer, as well as translational approaches being applied to better study therapeutics that activate the interferon pathway against hematologic and solid tumors and identify the patients who may respond better to these therapeutics.
To learn more about the Immuno-Oncology 360° Conference, please visit IO360Summit.com. And to read more about Dr Ward's work, click here.
Speakers
Related Podcasts
View All
The History of Tumor Vaccines, and Why the Newest RNA Vaccines May Work Where Others Could Not
Combining AI and Empirical Science to Advance Cancer Immunotherapies
Getting Under the Hood of AI to Find Its Value for Immuno-Oncology
